Kintara Therapeutics (KTRA) - Quarterly EPS earnings growth

Official company branding of Kintara Therapeutics, Inc. (KTRA)

Kintara Therapeutics revenues are based on future sales of VAL-083 targeted therapy for glioblastoma. Quarterly net income per share dynamics clearly confirm this potential, with the metric currently standing at 29.60. However, liquidity shortages and restructuring are creating financial challenges. Despite this, Kintara Therapeutics maintains its authority among patients through its pursuit of treatment methods for severe brain tumors.

Kintara Therapeutics, Inc. (KTRA) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 11/17/2026

Analytical breakdowns for Kintara Therapeutics

- market value and analyst target forecast:
Fundamental company analysis:kintara.com, KTRA
Manufactured product of Kintara Pharma

This indicator measures the quarterly dynamics of earnings per share, allowing for a real-time assessment of business model sustainability by comparing revenue and expense growth rates. For Kintara Therapeutics (KTRA), the relative growth of quarterly EPS is critical: success in developing brain cancer drugs will ensure an explosive surge in margins due to low synthesis costs during global sales scaling.

Analysis of competing companies

Incyte Corporation (INCY) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share growth for the last 12 months HUTCHMED Corp|NUVB (nuvationbio.com) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months dayonebio.com (DAWN)|Year-over-year earnings per share growth for the last twelve months Monopar Corp (MNPR)|INBX - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months I-Mab Inc. IMAB|Fennec - Year-over-year earnings per share growth for the last twelve months|HRTX - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Nuvectis Pharma, Inc.|CHRS: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Corbus Pharma CRBP|Year-over-year net earnings per share growth for the last 12 months CRDF|Earnings per share growth in annualized terms for the last twelve months BeyondSpring Inc. BYSI|Year-over-year net earnings per share growth for the last 12 months BCAB (BioAtla Inc)|LIXT (Lixte Biotechnology Holdings, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Citius Pharmaceuticals, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months CLRB (Cellectar Biosciences, Inc.)|BioLineRx Corp - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months CANF (Can-Fite BioPharma, Ltd.)|APRE: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Kazia (KZIA)|Year-over-year earnings per share growth for the last twelve months silexion.com|NCNA: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth CMRX|Quarterly EPS earnings growth Cyclacel, Inc. (CYCC)|Year-over-year earnings per share growth for the last twelve months G1 Therapeutics Inc. GTHX|KRON (Kronos Bio) - Year-over-year net earnings per share trend for the last twelve months|ONCT: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months Portage Biotech Inc